drugset / Trial / NCT03245541
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
Phase 1/2
Active not recruiting
18 enrolled
Memorial Sloan Kettering Cancer Center
AstraZeneca · collabCedars-Sinai Medical Center · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out if combining durvalumab with standard stereotactic ablative radiotherapy (SABR) is an effective treatment for people with locally advanced or borderline resectable pancreatic cancer. The researchers will also look at the safety of the combination treatment and any side effects it causes.
Timeline
- Start
- 2020-08-14
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |